Perspective Therapeutics Updates Interim Results of 212PbVMT-alpha-NET Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy CATX?
Perspective Therapeutics announced updated interim results from its ongoing Phase 1/2a clinical trial of 212PbVMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, taking place January 8-10 in San Francisco, CA. Interim results with a data cut-off date of December 10, 2025 formed the basis of the ASCO-GI update. The presentation includes safety data from 56 patients across three dose cohorts who have received at least one treatment of 212PbVMT-alpha-NET, and efficacy analysis from two patients in Cohort 1 and 23 of the patients in Cohort 2. Results with a data cut-off date of September 12, 2025 were previously presented at the European Society for Medical Oncology Congress 2025 in October 2025. At ESMO, the Company reported safety data on 55 patients across three dose cohorts who had received at least one treatment of 212PbVMT-alpha-NET and interim efficacy data for two patients in Cohort 1 and 23 patients in Cohort 2.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CATX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CATX
Wall Street analysts forecast CATX stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.550
Low
4.00
Averages
11.82
High
18.00
Current: 4.550
Low
4.00
Averages
11.82
High
18.00
About CATX
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wedbush Analyst Reiterates Outperform Rating for CATX
- Clinical Trial Update: Perspective Therapeutics presented updated clinical data for its VMT-a-NET program at the AACR Annual Meeting, with 64 patients treated to date, demonstrating efficacy in neuroendocrine tumor treatment, and is on track to complete nearly one year of follow-up for 46 patients by mid-2026.
- Positive Market Outlook: Analyst David Nierengarten reiterated an Outperform rating for CATX with a 12-month price target of $11, reflecting confidence in the company's growth potential, especially with meaningful data and regulatory catalysts expected in the near future.
- Competitive Advantage: With SNY deprioritizing AlphaMedix, VMT-a-NET is positioned as a frontrunner in targeted alpha therapy, further solidifying its market position and potentially attracting more investor interest.
- Stock Performance Review: CATX has traded between $1.86 and $6.16 over the past year, closing at $4.55 on Monday with an 8.33% increase, indicating a positive market reaction to its clinical advancements.
See More
Perspective Therapeutics to Attend Investor Conferences
- Investor Conference Participation: Perspective Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, engaging in presentations and one-on-one meetings with investors, which is expected to enhance the company's visibility and credibility among investors.
- Clinical Trial Progress: The company is conducting Phase 1/2a imaging and therapy trials for neuroendocrine tumors, melanoma, and solid tumors, utilizing its proprietary 212Pb isotope technology aimed at improving treatment efficacy and minimizing toxicity, potentially attracting more investor interest in its R&D capabilities.
- Technological Innovation: Perspective's
See More
Perspective Therapeutics Upgraded to Buy Rating
- Rating Upgrade: Perspective Therapeutics (CATX) has received an upgrade to a 'Buy' rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $12.93, reflecting confidence in the company's growth potential, and if achieved, the stock price could see significant upside.
- Market Reaction Anticipation: The upgrade in rating and price target is likely to stimulate a positive market reaction towards CATX, potentially driving the stock price higher and boosting investor confidence.
- Increased Investor Attention: With the improved rating, CATX may attract more institutional investors, further enhancing its market liquidity and shareholder value.
See More
Perspective Therapeutics Reports Disappointing FY Results
- Disappointing Earnings: Perspective Therapeutics reported a FY non-GAAP EPS of -$1.40, missing expectations by $0.20, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s revenue of $0.9 million represents a 37.9% year-over-year decrease, falling short of expectations by $0.17 million, reflecting weak market demand that could hinder future growth.
- Decreased Cash Reserves: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled approximately $145 million, down from $227 million in 2024, indicating increased liquidity pressure that may affect future investments and operational capabilities.
- Equity Financing Plan: Perspective Therapeutics announced a $175 million equity offering, which may alleviate short-term funding pressures but could dilute existing shareholders' stakes, impacting shareholder value.
See More
Perspective Therapeutics to Announce Q4 Earnings on March 16
- Earnings Announcement: Perspective Therapeutics is set to release its Q4 earnings on March 16 after market close, with consensus estimates predicting an EPS of -$0.34 and revenue of $0.24 million, providing crucial insights into the company's financial health.
- Equity Offering: The company recently priced a $175 million equity offering, which will support its ongoing research in the SSTR2 solid tumor targeting space, potentially enhancing its market competitiveness and future growth prospects.
- Market Reaction: Following the equity offering announcement, shares of Perspective Therapeutics saw an uptick, indicating increased investor confidence in the company's future, which may set a positive tone for the upcoming earnings report.
- Industry Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, further elevating its visibility among investors and within the industry, showcasing its ongoing efforts and strategic positioning in the tumor targeting treatment sector.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
Wedbush Analyst Reiterates Outperform Rating for CATX
- Clinical Trial Update: Perspective Therapeutics presented updated clinical data for its VMT-a-NET program at the AACR Annual Meeting, with 64 patients treated to date, demonstrating efficacy in neuroendocrine tumor treatment, and is on track to complete nearly one year of follow-up for 46 patients by mid-2026.
- Positive Market Outlook: Analyst David Nierengarten reiterated an Outperform rating for CATX with a 12-month price target of $11, reflecting confidence in the company's growth potential, especially with meaningful data and regulatory catalysts expected in the near future.
- Competitive Advantage: With SNY deprioritizing AlphaMedix, VMT-a-NET is positioned as a frontrunner in targeted alpha therapy, further solidifying its market position and potentially attracting more investor interest.
- Stock Performance Review: CATX has traded between $1.86 and $6.16 over the past year, closing at $4.55 on Monday with an 8.33% increase, indicating a positive market reaction to its clinical advancements.
See More
Perspective Therapeutics to Attend Investor Conferences
- Investor Conference Participation: Perspective Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, engaging in presentations and one-on-one meetings with investors, which is expected to enhance the company's visibility and credibility among investors.
- Clinical Trial Progress: The company is conducting Phase 1/2a imaging and therapy trials for neuroendocrine tumors, melanoma, and solid tumors, utilizing its proprietary 212Pb isotope technology aimed at improving treatment efficacy and minimizing toxicity, potentially attracting more investor interest in its R&D capabilities.
- Technological Innovation: Perspective's
See More
Perspective Therapeutics Upgraded to Buy Rating
- Rating Upgrade: Perspective Therapeutics (CATX) has received an upgrade to a 'Buy' rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $12.93, reflecting confidence in the company's growth potential, and if achieved, the stock price could see significant upside.
- Market Reaction Anticipation: The upgrade in rating and price target is likely to stimulate a positive market reaction towards CATX, potentially driving the stock price higher and boosting investor confidence.
- Increased Investor Attention: With the improved rating, CATX may attract more institutional investors, further enhancing its market liquidity and shareholder value.
See More
Perspective Therapeutics Reports Disappointing FY Results
- Disappointing Earnings: Perspective Therapeutics reported a FY non-GAAP EPS of -$1.40, missing expectations by $0.20, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s revenue of $0.9 million represents a 37.9% year-over-year decrease, falling short of expectations by $0.17 million, reflecting weak market demand that could hinder future growth.
- Decreased Cash Reserves: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled approximately $145 million, down from $227 million in 2024, indicating increased liquidity pressure that may affect future investments and operational capabilities.
- Equity Financing Plan: Perspective Therapeutics announced a $175 million equity offering, which may alleviate short-term funding pressures but could dilute existing shareholders' stakes, impacting shareholder value.
See More
Perspective Therapeutics to Announce Q4 Earnings on March 16
- Earnings Announcement: Perspective Therapeutics is set to release its Q4 earnings on March 16 after market close, with consensus estimates predicting an EPS of -$0.34 and revenue of $0.24 million, providing crucial insights into the company's financial health.
- Equity Offering: The company recently priced a $175 million equity offering, which will support its ongoing research in the SSTR2 solid tumor targeting space, potentially enhancing its market competitiveness and future growth prospects.
- Market Reaction: Following the equity offering announcement, shares of Perspective Therapeutics saw an uptick, indicating increased investor confidence in the company's future, which may set a positive tone for the upcoming earnings report.
- Industry Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, further elevating its visibility among investors and within the industry, showcasing its ongoing efforts and strategic positioning in the tumor targeting treatment sector.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
